Abstract
The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Current Medicinal Chemistry
Title: The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine
Volume: 9 Issue: 1
Author(s): M. Opincariu, A. Varro, N. Iost, L. Virag, O. Hala, J. Szolnoki, J. Szecsi, G. Bogats, P. Szenohradszky, P. Matyus and J. Gy. Papp
Affiliation:
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Abstract: The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Export Options
About this article
Cite this article as:
Opincariu M., Varro A., Iost N., Virag L., Hala O., Szolnoki J., Szecsi J., Bogats G., Szenohradszky P., Matyus P. and Gy. Papp J., The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine, Current Medicinal Chemistry 2002; 9 (1) . https://dx.doi.org/10.2174/0929867023371517
DOI https://dx.doi.org/10.2174/0929867023371517 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Eluting Stents and Beyond
Current Pharmaceutical Design Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Possible Therapies of Septic Shock: Based on Animal Studies and Clinical Trials
Current Pharmaceutical Design Cross-talk Between Exogenous Statins and Endogenous High-Density Lipoprotein in Anti-Inflammatory and Anti-Atherogenic Actions
Endocrine, Metabolic & Immune Disorders - Drug Targets N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Feasibility of Transcutaneous Method for Carbon Dioxide Monitoring in an Intensive Care Unit
Current Respiratory Medicine Reviews Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis
Current Pharmaceutical Design Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science Two-Dimensional (2D) In Silico Models for Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME/T) in Drug Discovery
Current Topics in Medicinal Chemistry Integrative Approaches for microRNA Target Prediction: Combining Sequence Information and the Paired mRNA and miRNA Expression Profiles
Current Bioinformatics Cardiovascular Comorbidities of COPD: When Do they Occur and How are they Managed?
Current Respiratory Medicine Reviews Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery